RELATIONSHIP BETWEEN LIVER GRAFT CYTOCHROME-P-450 3A AND ACUTE CYCLOSPORINE-INDUCED TOXICITY IN LIVER-TRANSPLANTATION

被引:0
作者
LEMOINE, A
AZOULAY, D
KIFFEL, L
GRIES, JM
BISMUTH, H
DEBUIRE, B
BEAUNE, P
机构
[1] HOP PAUL BROUSSE,CTR HEPATOBILIAIRE,VILLEJUIF,FRANCE
[2] UNIV PARIS 05,CHU NECKER,INSERM,U75,PARIS,FRANCE
来源
THERAPIE | 1994年 / 49卷 / 03期
关键词
CYTOCHROME P-450; ORTHOTOPIC LIVER TRANSPLANTATION; CYCLOSPORINE; TOXICITY;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the availability of whole blood cyclosporine assays, the different response of individual patients to its administration following transplantation continue to pose clinical problems, particularly in respect of toxicity. The aim of this study was to know if the inter-individual variations in the hepatic concentration of cytochrome P-450 3A, that metabolizes cyclosporine into several metabolites with very limited immunosuppressive activity, could be associated with cyclosporine toxicity. 59 consecutive liver transplant recipients were studied. Immunosuppression was with cyclosporine, azathioprine and methylprednisolone. The relative concentration of P-450 3A was assessed by immunoblot analysis using a specific monoclonal antibody on liver graft biopsy. Twelve patients experienced toxic neurological and renal complications. Six of these patients had cyclosporine levels in the therapeutic range. There was an excellent correlation between the occurrence of complications and cyclosporine whole blood levels (P < 10(-4)), the first day post-op after a standard dose of cyclosporine (1 mg/kg). Cytochrome P-450 3A hepatic content assessed in a groupe of 34 patients exhibited a 10-fod variation (m = 94 +/- 47 AU (Arbitrary Units)/mg). Eight of these patients who developped cyclosporine toxicity had a lower graft P-450 3A levels (m = 52 +/- 19 AU/mg, P = 3.10(-4), cf. patients with no toxicity). This highlights the importance of the first dose of cyclosporine and indicates that cytochrome P-450 3A can provide information which should allow individualized immunosuppression with cyclosporine maintaining therapeutic levels but avoiding toxicity in susceptible individuals.
引用
收藏
页码:279 / 282
页数:4
相关论文
共 16 条
[1]  
ADAMS DH, 1987, LANCET, V1, P949
[2]  
AZOULAY D, 1993, TRANSPLANT P, V25, P2275
[3]  
BEAUNE PH, 1986, DRUG METAB DISPOS, V14, P437
[4]  
BERTAULTPERES P, 1987, DRUG METAB DISPOS, V15, P391
[5]   EFFECT OF CYCLOSPORINE, CYCLOSPORINE METABOLITE-17, AND OTHER CYCLOSPORINE-RELATED COMPOUNDS ON LYMPHOCYTE-T CLONES DERIVED FROM REJECTED HUMAN-KIDNEY GRAFTS [J].
CHABANNES, D ;
MOREAU, JF ;
SOULILLOU, JP .
TRANSPLANTATION, 1987, 44 (06) :813-817
[6]   CYCLOSPORINE - A REVIEW AND ITS SPECIFIC USE IN LIVER-TRANSPLANTATION [J].
DEGROEN, PC .
MAYO CLINIC PROCEEDINGS, 1989, 64 (06) :680-689
[7]   CENTRAL-NERVOUS-SYSTEM TOXICITY AFTER LIVER-TRANSPLANTATION - THE ROLE OF CYCLOSPORINE AND CHOLESTEROL [J].
DEGROEN, PC ;
AKSAMIT, AJ ;
RAKELA, J ;
FORBES, GS ;
KROM, RAF .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (14) :861-866
[8]   RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES [J].
FEUTREN, G ;
MIHATSCH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (25) :1654-1660
[9]   PREDICTING STEADY-STATE SERUM CONCENTRATIONS OF DRUGS [J].
GREENBLATT, DJ .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1979, 19 :347-356
[10]  
GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051